Excluding certain noncash charges, the loss for the third quarter was $561,000, or 3 cents a share. According to a
First Call/Thomson Financial
consensus estimate, six analysts were looking for a loss of 5 cents a share. The company lost 7 cents a share in the year-ago period before noncash items.
The genetics research company said third-quarter revenue rose to $823,000 from $630,000 a year ago. The company credited its Universal GeneTools product and its partnership with
as the primary revenue source during the third quarter.